Toll Free: 1-888-928-9744

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

Published: Jun 1, 2016 | Pages: 73 | Publisher: GBI Research | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

Summary

Diabetes is a common long-term condition that can lead to a range of disparate and serious complications. It is a lifelong, multi-systemic condition that affects a number of integral organs. Diabetes has a rapidly increasing prevalence – it currently affects 10% of adults globally, and is estimated to become the seventh-leading cause of death by 2030.

The lack of absolute treatment for the condition and the difficulty in maintaining constant glycemic control, even following adequate treatment, can result in a range of complications. The three main indication groups are diabetic nephropathy, which is a progressive condition caused by damage to the capillaries and kidneys glomeruli as a result of diabetes; diabetic retinopathy, which is defined as damage to the retina as a result of high blood sugar; and a range of diabetic neuropathies, a group of conditions in which nerve damage is caused as a result of diabetes mellitus.

The need for improved therapeutics within diabetic complications is especially prominent in comparison with other multi-systemic conditions, as the market is currently predominantly composed of therapies that symptomatically treat the condition, or at best slow disease progression. However, as the understanding of disease pathophysiology in both diabetes and its complications increases, new targets are being identified and converted into improved therapeutic options that are better aligned with the underlying disease pathophysiology than their predecessors.

The diabetic complications pipeline consists of 429 products that contain an array of targets not currently in use within the market. The increase in molecular target diversity signifies the high potential for changes and improvements in the diabetic complications market. One innovative therapy is CBX-129801, a promising synthetic peptide that is currently in development for diabetic neuropathy. Innovation can also be seen within diabetic retinopathy, with therapies such as BCN070660, a topical ophthalmologic formulation currently in development.

Scope

- What effect do current market therapies have on disease progression?
- Which drug classes dominate the current market?
- What additional benefits have newly approved therapies brought to the market?
- Can the increasing number of peptides in the pipeline prove useful in diabetic neuropathy?
- Can neuroprotective therapies prove an important addition in diabetic retinopathies?
- Can the diverse range of molecule types and molecular targets within the pipeline help reverse disease progression?
- To what degree is the pipeline penetrated by first-in-class innovation?
- What is the clinical potential of first-in-class products, based on their alignment to disease-causing pathways?
- Which are the most promising first-in-class targets in early-stage development?
- Which of the first-in-class products in development are not currently involved in a licensing or co-development deal, and therefore represent investment opportunities?

Reasons to buy

- Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
- Visualize the composition of the market for each diabetic complication individually, in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the pipeline for each diabetic complication individually and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking more innovative approaches to treating diabetic complications.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
- Identify commercial opportunities in the diabetic complications deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of diabetic complications therapies that are not yet involved in deals, and may be potential investment opportunities.
 Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 5
2.1 Significant Unmet Needs in Diabetic Complications Market 5
2.2 High Proportion of First-in-Class Innovation Offers Promise in Diabetic Complications 5
2.3 Deal Activity Varies with First-in-Class Status 5

3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Development Remains Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 8

4 Clinical and Commercial Landscape 10
4.1 Diabetes Mellitus Overview 10
4.2 Diabetic Neuropathies 11
4.2.1 Disease Overview 11
4.2.2 Signs and Symptoms 11
4.2.3 Epidemiology and Etiology 12
4.2.4 Pathophysiology 12
4.2.5 Diagnosis and Staging 12
4.2.6 Prognosis 13
4.2.7 Treatment Options 13
4.3 Diabetic Nephropathy 14
4.3.1 Disease Overview 14
4.3.2 Sign and Symptoms 14
4.3.3 Epidemiology and Etiology 14
4.3.4 Pathophysiology 14
4.3.5 Diagnosis and Staging 14
4.3.6 Prognosis 15
4.3.7 Treatment Options 15
4.4 Diabetic Retinopathies 16
4.4.1 Disease Overview 16
4.4.2 Signs and Symptoms 16
4.4.3 Epidemiology and Etiology 16
4.4.4 Pathophysiology 16
4.4.5 Diagnosis and Staging 17
4.4.6 Prognosis 17
4.4.7 Treatment Options 17
4.5 Overview of Marketed Products in Diabetic Complications 18
4.5.1 Overview of Marketed Products in Diabetic Neuropathies 18
4.5.2 Overview of Marketed Products in Diabetic Nephropathy 20
4.5.3 Overview of Marketed Products in Diabetic Retinopathies 20

5 Assessment of Pipeline Product Innovation 22
5.1 Diabetic Neuropathies by Molecule Type, Phase and Therapeutic Target 22
5.1.1 Comparative Distribution of Programs between Diabetic Neuropathy Market and Pipeline by Therapeutic Target Family 24
5.1.2 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 25
5.2 Diabetic Nephropathy by Molecule Type, Phase and Therapeutic Target 27
5.2.1 Comparative Distribution of Programs between the Diabetic Nephropathy Market and Pipeline by Therapeutic Target Family 29
5.2.2 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 30
5.3 Diabetic Retinopathies by Molecule Type, Phase and Therapeutic Target 32
5.3.1 Comparative Distribution of Programs between the Diabetic Retinopathy Market and Pipeline by Therapeutic Target Family 34
5.3.2 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 35
5.3.3 Pipeline Products in Diabetic Complications 38

6 Signaling Network, Disease Causation and Innovation Alignment 41
6.1 Complexity of Signaling Networks in Metabolic Disorders 41
6.2 First-in-Class Matrix Assessment 42

7 First-in-Class Target Evaluation 44
7.1 Pipeline Programs Targeting NADPH Oxidase 4 44
7.2 Pipeline Programs Targeting Glutamate Decarboxylase 45
7.3 Pipeline Programs Targeting Growth Hormone Secretagogue Receptor Type 1 46
7.4 Pipeline Programs Targeting Motilin Receptor 47
7.5 Pipeline Programs Targeting Lysophosphatidic Acid Receptor 1 48
7.6 Pipeline Programs Targeting Leukotriene B4 Receptor 1 50
7.7 Pipeline Programs Targeting Integrin Alpha V 51
7.8 Pipeline Programs Targeting Signal Transducer and Activator of Transcription 4 53

8 Deals and Strategic Consolidations 54
8.1 Industry-Wide First-in-Class Deals 54
8.2 Licensing Deals 55
8.2.1 Licensing Deals by Molecule Type 57
8.2.2 Licensing Deals by Molecular Target 57
8.3 Co-development Deals 59
8.3.1 Co-development Deals by Molecule Type 60
8.3.2 Co-development Deals by Molecular Target 60
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals 62

9 Appendix 66
9.1 References 66
9.2 Abbreviations 71
9.3 Research Methodology 71
9.4 Secondary Research 72
9.4.1 Market Analysis 72
9.4.2 Pipeline Analysis 72
9.4.3 First-in-Class Matrix Assessment 72
9.4.4 First-in-Class Target Profiles 73
9.4.5 Licensing and Co-Development Deals 73
9.5 Contact Us 73
9.6 Disclaimer 73
List of Tables

Table 1: Natural Development of Diabetic Nephropathy 15
Table 2: Diabetic Complications, Global, Data for NADPH Oxidase 4 as Therapeutic Target, 2016 44
Table 3: Diabetic Complications, Global, Data for Glutamate Decarboxylase as Therapeutic Target, 2016 46
Table 4: Diabetic Complications, Global, Data for Growth Hormone Secretagogue Receptor Type 1 as Therapeutic Target, 2016 47
Table 5: Diabetic Complications, Global, Data for Motilin Receptor as Therapeutic Target, 2016 48
Table 6: Diabetic Complications, Global, Data for Lysophosphatidic Acid Receptor 1 as Therapeutic Target, 2016 49
Table 7: Diabetic Complications, Global, Data for Leukotriene B4 Receptor 1 as Therapeutic Target, 2016 50
Table 8: Diabetic Complications, Global, Data for Integrin Alpha V as Therapeutic Target, 2016 52
Table 9: Diabetic Complications, Global, Data for Signal Transducer and Activator of Transcription 4 as Therapeutic Target, 2016 53
Table 10: Abbreviations 71

List of Figures

Figure 1: Diabetic Complications, Global, Number of Product Approvals by FDA and Five-Year Moving Average of Product Approvals (%), 1987–2012 6
Figure 2: Global, Sales Performance of First-in-Class and Non-First-in-Class Products after Marketing Approval ($m), 2016 8
Figure3: Diabetic Neuropathies, Global, Overview of Marketed Products, 2016 19
Figure 4: Diabetic Nephropathy, Global, Overview of Marketed Products, 2016 20
Figure 5: Diabetic Retinopathies, Global, Overview of Marketed Products, 2016 21
Figure 6: Diabetic Neuropathies, Global, Overview of Pipeline Products, 2016 23
Figure 7: Diabetic Neuropathies, Global, Molecular Targets in Pipeline, 2016 24
Figure 8: Diabetic Neuropathies, Global, Pipeline by Molecular Targets and Stage of Development, 2016 24
Figure 9: Diabetic Neuropathies, Global, Molecular Target Family Comparison, Pipeline and Marketed Products, 2016 25
Figure 10: Diabetic Neuropathies, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2016 26
Figure 11: Diabetic Neuropathies, Global, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%), 2016 27
Figure 12: Diabetic Neuropathies, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%), 2016 27
Figure 13: Diabetic Nephropathy, Global, Overview of Pipeline Products, 2016 28
Figure 14: Diabetic Nephropathy, Global, Molecular Targets in Pipeline, 2016 29
Figure 15: Diabetic Nephropathy, Global, Pipeline by Molecular Targets and Stage of Development, 2016 29
Figure 16: Diabetic Nephropathy, Global, Molecular Target Family Comparison, Pipeline and Marketed Products, 2016 30
Figure 17: Diabetic Nephropathy, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2016 31
Figure 18: Diabetic Nephropathy, Global, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%), 2016 32
Figure 19: Diabetic Nephropathy, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%), 2016 32
Figure 20: Diabetic Retinopathies, Global, Overview of Pipeline Products, 2016 33
Figure 21: Diabetic Retinopathies, Global, Molecular Targets in Pipeline, 2016 34
Figure 22: Diabetic Retinopathies, Global, Pipeline by Molecular Targets and Stage of Development, 2016 34
Figure 23: Diabetic Retinopathies, Global, Complications, Molecular Target Family Comparison, Pipeline and Marketed Products, 2016 35
Figure 24: Diabetic Retinopathies, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2016 36
Figure 25: Diabetic Retinopathies, Global, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%), 2016 37
Figure 26: Diabetic Retinopathies, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%), 2016 37
Figure 27: Diabetic Complications, Global, First-in-Class Products in Pipeline (Part 1), 2016 38
Figure 28: Diabetic Complications, Global, First-in-Class Products in Pipeline (Part 2), 2016 39
Figure 29: Diabetic Complications, Global, First-in-Class Products in Pipeline (Part 3), 2016 40
Figure 30: Diabetic Complications, Global, Gastric Cancer, Target Matrix, 2016 43
Figure 31: Diabetic Complications, Global, Pipeline Programs Targeting NADPH Oxidase 4, 2016 45
Figure 32: Diabetic Complications, Global, Pipeline Programs Targeting Glutamate Decarboxylase, 2016 46
Figure 33: Diabetic Complications, Global, Pipeline Programs Targeting Growth Hormone Secretagogue Receptor Type 1, 2016 47
Figure 34: Diabetic Complications, Global, Pipeline Programs Targeting Motilin Receptor, 2016 48
Figure 35: Diabetic Complications, Global, Pipeline Programs Targeting Lysophosphatidic Acid Receptor 1, 2016 49
Figure 36: Diabetic Complications, Global, Pipeline Programs Targeting Leukotriene B4 Receptor 1, 2016 51
Figure 37: Diabetic Complications, Global, Pipeline Programs Targeting Integrin Alpha V, 2016 52
Figure 38: Diabetic Complications, Global, Pipeline Programs Targeting Signal Transducer and Activator of Transcription 4, 2016 53
Figure 39: Diabetic Complications, Global, Deals by Stage of Development, 2006–2014 54
Figure 40: Diabetic Complications, Global, Licensing Deal Values by Stage of Development ($m), 2006–2014 55
Figure 41: Diabetic Complications, Global, Licensing Deal Value, 2006–2016 56
Figure 42: Diabetic Complications, Global, Licensing Deals by Year, 2006–2016 56
Figure 43: Diabetic Complications, Global, Licensing Deals by Stage of Development, 2006–2016 56
Figure 44: Diabetic Complications, Global, Licensing Deal Value by Stage of Development and Molecule Type, 2006–2016 57
Figure 45: Diabetic Complications, Global, Licensing Deal Value by Molecular Target, 2006–2016 57
Figure 46: Diabetic Complications, Global, Summary of Licensing Deals, 2006–2016 58
Figure 47: Diabetic Complications, Global, Co-development Deal Value, 2006–2016 59
Figure 48: Diabetic Complications, Global, Co-development Deals, 2006–2016 59
Figure 49: Diabetic Complications, Global, Co-development Deals by Stage of Development, 2006–2016 60
Figure 50: Diabetic Complications, Global, Co-development by Stage of Development and Molecule Type, 2006–2015 60
Figure 51: Diabetic Complications, Global, Co-development by Stage of Development and Molecular Target, 2006–2015 61
Figure 52: Diabetic Complications, Global, Summary of Co-development Deals, 2006-2016 62
Figure 53: Diabetic Complications, Global, First-in-Class Therapies Not Involved in Deals (Part 1), 2016 63
Figure 54: Diabetic Complications, Global, First-in-Class Therapies Not Involved in Deals (Part 2), 2016 64
Figure 55: Diabetic Complications, Global, First-in-Class Therapies Not Involved in Deals (Part 3), 2016 65 



To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption rat

Read More...

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet o

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...

Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likely

Read More...
Choose License Type
Single User - US $6995
Multi User - US $13990
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify